Bruce McCreedy, PhD
Chief Scientific Officer
Bruce McCreedy has over three decades of experience in the development and approval of drugs for the treatment of cancer, autoimmune disorders, and infectious diseases.
He joined ONK Therapeutics as CSO in December 2022.
Previously, Bruce was Chief Science Officer at Myeloid Therapeutics, a clinical stage immunology company. He has also served as Senior Vice President Cell Therapy and Immuno-Oncology Research at Precision BioSciences, Inc.where he oversaw the development of a portfolio of gene edited allogeneic CAR T therapies.
Previous industry positions held by Bruce include Executive Vice President and Chief Development Officer for Neximmune, Inc., President and CEO of Fulcrum Pharma Developments, Inc. and Vice President of Clinical Virology and Diagnostics for Triangle Pharmaceuticals, Inc. (now Gilead Sciences).
Bruce obtained a PhD in Microbiology and Immunology from the School of Medicine, Wake Forest University, North Carolina.